Net Income (Loss) Attributable to Parent in USD of INOVIO PHARMACEUTICALS, INC. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
INOVIO PHARMACEUTICALS, INC. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • INOVIO PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$45.5M, a 80.8% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$108M, a 4.24% increase year-over-year.
  • INOVIO PHARMACEUTICALS, INC. annual Net Income (Loss) Attributable to Parent for 2024 was -$107M, a 20.6% increase from 2023.
  • INOVIO PHARMACEUTICALS, INC. annual Net Income (Loss) Attributable to Parent for 2023 was -$135M, a 51.7% increase from 2022.
  • INOVIO PHARMACEUTICALS, INC. annual Net Income (Loss) Attributable to Parent for 2022 was -$280M, a 7.85% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

INOVIO PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$108M -$45.5M -$20.3M -80.8% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025
Q2 2025 -$87.8M -$23.5M +$8.72M +27% 01 Apr 2025 30 Jun 2025 10-Q 10 Nov 2025
Q1 2025 -$96.5M -$19.7M +$10.8M +35.4% 01 Jan 2025 31 Mar 2025 10-Q 10 Nov 2025
Q4 2024 -$107M -$19.4M +$5.62M +22.5% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025
Q3 2024 -$113M -$25.2M +$8.76M +25.8% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025
Q2 2024 -$122M -$32.2M +$3.3M +9.28% 01 Apr 2024 30 Jun 2024 10-Q 10 Nov 2025
Q1 2024 -$125M -$30.5M +$10.2M +25% 01 Jan 2024 31 Mar 2024 10-Q 10 Nov 2025
Q4 2023 -$135M -$25M +$29.5M +54.1% 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025
Q3 2023 -$165M -$33.9M +$3.85M +10.2% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$168M -$35.5M +$73M +67.2% 01 Apr 2023 30 Jun 2023 10-Q 14 Nov 2024
Q1 2023 -$241M -$40.6M +$38.4M +48.6% 01 Jan 2023 31 Mar 2023 10-Q 14 Nov 2024
Q4 2022 -$280M -$54.5M +$52.5M +49.1% 01 Oct 2022 31 Dec 2022 10-K 06 Mar 2024
Q3 2022 -$332M -$37.8M +$22.4M +37.2% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$355M -$108M -$26.4M -32.1% 01 Apr 2022 30 Jun 2022 10-Q 09 Nov 2023
Q1 2022 -$328M -$79.1M -$24.7M -45.4% 01 Jan 2022 31 Mar 2022 10-Q 09 Nov 2023
Q4 2021 -$304M -$107M -$82.6M -339% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2024
Q3 2021 -$221M -$60.2M -$79.3M -414% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022
Q2 2021 -$142M -$82.1M +$46.6M +36.2% 01 Apr 2021 30 Jun 2021 10-Q 08 Nov 2022
Q1 2021 -$188M -$54.4M -$21.9M -67.2% 01 Jan 2021 31 Mar 2021 10-Q 08 Nov 2022
Q4 2020 -$166M -$24.3M +$13.3M +35.4% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2021
Q3 2020 -$180M $19.2M +$42.3M 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 -$222M -$129M -$99.3M -338% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 -$123M -$32.5M -$3.32M -11.4% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021
Q4 2019 -$119M -$37.7M -$4.7M -14.3% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2021
Q3 2019 -$115M -$23.1M +$1.92M +7.7% 01 Jul 2019 30 Sep 2019 10-K 01 Mar 2021
Q2 2019 -$117M -$29.4M -$22.7M -343% 01 Apr 2019 30 Jun 2019 10-K 01 Mar 2021
Q1 2019 -$93.8M -$29.2M +$3.13M +9.68% 01 Jan 2019 31 Mar 2019 10-K 01 Mar 2021
Q4 2018 -$97M -$33M -$11.5M -53.3% 01 Oct 2018 31 Dec 2018 10-K 01 Mar 2021
Q3 2018 -$85.5M -$25M +$9.12M +26.7% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$94.6M -$6.64M +$2.84M +30% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019
Q1 2018 -$97.5M -$32.4M -$9.26M -40.1% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 -$88.2M -$21.5M +$4.73M +18% 01 Oct 2017 31 Dec 2017 10-K 14 Mar 2018
Q3 2017 -$92.9M -$34.1M -$13.4M -64.4% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018
Q2 2017 -$79.6M -$9.48M +$9.23M +49.3% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018
Q1 2017 -$88.8M -$23.1M -$15M -187% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018
Q4 2016 -$73.7M -$26.2M -$8.28M -46.1% 01 Oct 2016 31 Dec 2016 10-K 14 Mar 2018
Q3 2016 -$65.5M -$20.8M -$26.4M -471% 01 Jul 2016 30 Sep 2016 10-K 14 Mar 2018
Q2 2016 -$39.1M -$18.7M -$12.5M -199% 01 Apr 2016 30 Jun 2016 10-K 14 Mar 2018
Q1 2016 -$26.6M -$8.04M +$2.54M +24% 01 Jan 2016 31 Mar 2016 10-K 14 Mar 2018
Q4 2015 -$29.2M -$18M -$10.5M -142% 01 Oct 2015 31 Dec 2015 10-K 15 Mar 2017
Q3 2015 -$18.6M $5.59M +$12.8M 01 Jul 2015 30 Sep 2015 10-K 15 Mar 2017
Q2 2015 -$31.4M -$6.25M +$4.46M +41.7% 01 Apr 2015 30 Jun 2015 10-K 15 Mar 2017
Q1 2015 -$35.9M -$10.6M +$240K +2.22% 01 Jan 2015 31 Mar 2015 10-K 15 Mar 2017
Q4 2014 -$36.1M -$7.41M +$8.04M +52% 01 Oct 2014 31 Dec 2014 10-K 14 Mar 2016
Q3 2014 -$44.2M -$7.18M +$23.7M +76.8% 01 Jul 2014 30 Sep 2014 10-K 14 Mar 2016
Q2 2014 -$67.9M -$10.7M +$141K +1.3% 01 Apr 2014 30 Jun 2014 10-K 14 Mar 2016
Q1 2014 -$68M -$10.8M -$1.98M -22.4% 01 Jan 2014 31 Mar 2014 10-K 14 Mar 2016
Q4 2013 -$66M -$15.5M -$14.8M -2246% 01 Oct 2013 31 Dec 2013 10-K 16 Mar 2015
Q3 2013 -$51.2M -$30.9M -$24.3M -366% 01 Jul 2013 30 Sep 2013 10-K 16 Mar 2015
Q2 2013 -$27M -$10.9M -$6.72M -163% 01 Apr 2013 30 Jun 2013 10-K 16 Mar 2015
Q1 2013 -$20.3M -$8.84M -$589K -7.14% 01 Jan 2013 31 Mar 2013 10-K 16 Mar 2015
Q4 2012 -$19.7M -$659K +$4.82M +88% 01 Oct 2012 31 Dec 2012 10-K 17 Mar 2014
Q3 2012 -$24.5M -$6.62M -$2.08M -45.8% 01 Jul 2012 30 Sep 2012 10-K 17 Mar 2014
Q2 2012 -$22.4M -$4.13M -$1.31M -46.5% 01 Apr 2012 30 Jun 2012 10-K 17 Mar 2014
Q1 2012 -$21.1M -$8.25M -$5.84M -242% 01 Jan 2012 31 Mar 2012 10-K 17 Mar 2014
Q4 2011 -$15.3M -$5.48M 01 Oct 2011 31 Dec 2011 10-K 18 Mar 2013
Q3 2011 -$4.54M -$3.13M -222% 01 Jul 2011 30 Sep 2011 10-K 18 Mar 2013
Q2 2011 -$2.82M +$4.79M +62.9% 01 Apr 2011 30 Jun 2011 10-K 18 Mar 2013
Q1 2011 -$2.41M 01 Jan 2011 31 Mar 2011 10-K 18 Mar 2013
Q3 2010 -$1.41M 01 Jul 2010 30 Sep 2010 10-Q 07 Nov 2011
Q2 2010 -$7.62M 01 Apr 2010 30 Jun 2010 10-Q 05 Aug 2011

INOVIO PHARMACEUTICALS, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$107M +$27.9M +20.6% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025
2023 -$135M +$145M +51.7% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025
2022 -$280M +$23.8M +7.85% 01 Jan 2022 31 Dec 2022 10-K 06 Mar 2024
2021 -$304M -$137M -82.5% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2024
2020 -$166M -$47.1M -39.4% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023
2019 -$119M -$22.4M -23.1% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022
2018 -$97M -$8.76M -9.93% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021
2017 -$88.2M -$14.5M -19.6% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020
2016 -$73.7M -$44.6M -153% 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019
2015 -$29.2M +$6.93M +19.2% 01 Jan 2015 31 Dec 2015 10-K 14 Mar 2018
2014 -$36.1M +$29.9M +45.3% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2017
2013 -$66M -$46.4M -236% 01 Jan 2013 31 Dec 2013 10-K 14 Mar 2016
2012 -$19.7M -$4.42M -29% 01 Jan 2012 31 Dec 2012 10-K 16 Mar 2015
2011 -$15.3M +$2.36M +13.4% 01 Jan 2011 31 Dec 2011 10-K 17 Mar 2014
2010 -$17.6M 01 Jan 2010 31 Dec 2010 10-K 18 Mar 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.